[Form 8-K Current Report](index=1&type=section&id=Form%208-K%20Current%20Report) [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) Bruker Corporation announced unaudited preliminary Q2 2025 financial results, subject to change before final release on August 4 - The company issued a press release on **July 21, 2025**, announcing unaudited preliminary results for **Q2 2025**[5](index=5&type=chunk) - Preliminary financial results are subject to completion of financial closing procedures and could change significantly[6](index=6&type=chunk) - Bruker expects to announce final **Q2 financial results** before market open on **August 4, 2025**[6](index=6&type=chunk) [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) Forward-looking statements on preliminary Q2 2025 revenue and performance are subject to risks and uncertainties - Statements regarding preliminary **Q2 2025 revenue and performance** are considered forward-looking[8](index=8&type=chunk) - Forward-looking statements are subject to risks and uncertainties, with actual results potentially differing materially, as detailed in SEC filings[8](index=8&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01.%20Financial%20Statements%20and%20Exhibits.) This section lists Form 8-K exhibits, including the preliminary Q2 2025 results press release and interactive data Exhibit List | Exhibit Number | Description | | :--- | :--- | | 99.1 | Press release dated July 21, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

Group 1: Optical Tweezers (OT) - Optical tweezers, invented by Arthur Ashkin in 1986, utilize laser light to manipulate microscopic objects without physical contact, minimizing damage to biological samples [4][5] - The technology has evolved over 40 years, expanding its application from micron-sized spheres to atomic and nanoscale objects, and is now a key tool in cell manipulation and biophysical research [4][5] - Major applications include single-molecule biology, assisted reproduction, and capturing rare cells, with companies like Changguang Chenying and Catcher representing the domestic market [5][10] Group 2: Optical Electric Tweezers (OET) - Optical electric tweezers, inspired by optical tweezers, were developed in 2005 and commercialized by Berkeley Lights in 2011, later acquired by Bruker in 2023 [2][17] - OET technology generates non-uniform electric fields to manipulate particles, allowing for high-throughput applications in cell sorting, analysis, and drug delivery [15][19] - The technology faces high barriers to entry due to complex know-how and high R&D costs, with few companies successfully commercializing it [17][18] Group 3: Industry Trends and Future Prospects - The integration of OET with microfluidics is transforming biopharmaceutical research, enabling high-throughput screening and antibody development [19][20] - Future trends include the automation of processes through AI, the introduction of new materials for better biocompatibility, and modular integration for compact systems [20] - Companies like Micronano Power and Catcher are leading innovations in the field, with products that enhance precision and efficiency in cell manipulation [23][12]

Core Viewpoint - The article discusses the advancements in animal hair identification in textiles using the MALDI-TOF mass spectrometry technology developed by Bruker, which addresses the challenges posed by traditional methods and enhances accuracy and reliability in detecting animal hair sources in textile products [1][2][12]. Group 1: Identification Challenges - Traditional methods for identifying animal hair in textiles, such as optical microscopy, are limited, especially when the samples undergo processing like bleaching or dyeing, which can damage DNA [1][2]. - Certain animal fibers, such as cashmere, sheep wool, and yak wool, have overlapping morphological characteristics, making it difficult to establish objective standards for identification [1]. Group 2: MALDI-TOF Technology Implementation - The Shanghai Customs Industrial Products and Raw Materials Testing Technology Center has established a national standard (GB/T 42699.2-2023) for the qualitative and quantitative analysis of animal hair fibers in textiles using MALDI-TOF-MS, which will be implemented in March 2024 [2]. - The MALDI-TOF-MS method allows for both accurate identification of animal hair sources and quantification of adulterated samples, demonstrating good reproducibility [2][11]. Group 3: Methodology and Results - The process involves extracting proteins from animal hair using SDS/DTT/phosphate buffer, purifying them through SDS-PAGE, and analyzing the resulting peptides with MALDI-TOF-MS to identify species based on characteristic peptide segments [3][4]. - Characteristic peptide segments for different animal species are concentrated in the mass-to-charge ratio range of 2450 m/z to 2750 m/z, allowing for precise identification [4][6]. Group 4: Performance and Reliability - The MALDI-TOF-MS method has shown excellent robustness with a relative standard deviation (RSD) of less than 5% over three years of testing different sample concentrations, ensuring data accuracy and reliability [11]. - The technology is not only applicable to textile analysis but can also be utilized in other fields, such as food adulteration detection [12].

Company Overview - Bruker Corporation (BRKR) has recently shipped and installed its 15th InSight WLI 3D optical metrology system for a leading semiconductor manufacturer, as part of a larger order for 27 systems in 2025 [1][8] - The InSight WLI system is designed for advanced packaging measurement requirements, providing non-contact, high-resolution 3D optical metrology essential for maintaining yield and quality in semiconductor manufacturing [6][8] Industry Context - The latest order highlights Bruker's integral role in the semiconductor industry's shift towards advanced packaging for AI chip manufacturing, which is crucial for meeting the demands of higher performance and energy efficiency in AI technologies [2][7] - The global advanced packaging market was valued at $38.50 billion in 2024 and is projected to grow at a compound annual growth rate of 11.5%, reaching $111.40 billion by 2034, driven by the increasing adoption of artificial intelligence [10] Financial Performance - Following the announcement of the new order, Bruker shares rose by 2.4%, closing at $39.66 [3] - Bruker has a market capitalization of $6.33 billion, with earnings expected to increase by 1.7% in 2025 according to the Zacks Consensus Estimate [5] Product Significance - Bruker's advanced metrology solutions are essential for addressing new manufacturing challenges introduced by advanced packaging, such as precision alignment and structural integrity, which are critical for AI workloads [7][8]

Core Viewpoint - The revenue of multinational instrument companies in China has generally declined in 2024, with only Merck achieving growth, while many companies have experienced consecutive declines over the past two years due to multiple factors including US-China trade tensions, economic environment, and market competition [1][2]. Revenue Performance Summary - In 2024, Merck led the revenue rankings in China with $32.98 billion, marking a 5.8% increase after a 14.2% decline in 2023 [5][6]. - Danaher followed with $28.05 billion, down 10.8%, continuing a downward trend from $31.43 billion in 2023, which was a 13.0% decrease [6][8]. - Agilent ranked third with $12.20 billion, a decline of 11.6%, following a 7.9% drop in 2023 [7][8]. - Shimadzu and Mettler-Toledo ranked fourth and fifth with revenues of $6.30 billion and $6.22 billion, respectively, both experiencing declines [8]. - Overall, over 80% of the listed companies saw a year-on-year revenue decrease in 2024, with some companies facing declines for two consecutive years [8][14]. Market Share Analysis - The market share of many companies in China has also shown a downward trend, reflecting poor performance and indicating a relative decline in market vitality compared to global markets [9]. - In 2024, Agilent's market share in China was 18.74%, down from over 20% in previous years, indicating a significant drop [9]. Company-Specific Insights - Danaher reported that approximately 12% of its sales come from China, highlighting the potential adverse effects of the political, economic, and regulatory environment on its business [11]. - Waters experienced a notable 30% decline in sales in China, attributed to decreased demand across various customer categories due to economic conditions and trade tensions [12]. - Agilent's revenue decline was primarily driven by pressures in capital spending from clients, particularly in the pharmaceutical market [12]. - Mettler-Toledo emphasized the importance of the Chinese market, which accounted for 16% of its external sales, and noted the impact of geopolitical tensions and economic pressures on its performance [13]. Strategic Adjustments - In response to market changes, multinational companies are accelerating strategic adjustments, increasing investment in local R&D, and launching products tailored to local needs [15]. - Despite the challenges faced from 2022 to 2024, the long-term potential of the Chinese market remains significant, and companies are expected to adapt more flexibly and innovatively to maintain competitiveness [15].

Summary of Bruker (BRKR) 2025 Conference Call Company Overview - **Company**: Bruker Corporation (BRKR) - **Event**: 2025 Conference Call held on June 04, 2025 Key Industry Insights - **Industry**: Mass Spectrometry and Proteomics - **Market Trends**: The mass spectrometry market is experiencing significant innovation, particularly in proteomics and metabolomics, with a focus on high sensitivity and throughput solutions [3][10][12] Core Product Innovations 1. **TIMS Ultra and AIP**: - New product launched to enhance MSMS sensitivity and bandwidth, allowing for more peptides and proteins to be analyzed [5][7] - Significant advancements in single-cell proteomics, enabling analysis of smaller cells than previously possible [8] 2. **TIMS Metabo Instrument**: - Aimed at the high-resolution accurate mass market for small molecules, targeting applications in PFAS research, toxicology, and metabolomics [11][12] - Expected to double the market opportunity for Bruker, potentially reaching a $200 million market share [15] 3. **TIMS Omni**: - A revolutionary mass spectrometer combining TIMS technology with Omni Trap, enabling top-down proteomics and functional proteomics [17][18] - Positioned to create a new category in mass spectrometry with no direct competition [19] Financial Outlook - **Revenue Guidance**: Anticipated moderate growth in 2026, with expectations of organic growth between 6% to 8% [32] - **Cost Management**: Bruker is implementing cost-cutting measures, including reducing operational costs in European sites and optimizing R&D spending [33][35] Market Dynamics - **Academic Market**: Anticipated decline in academic spending by 20-25% due to budget constraints, impacting overall revenue [22][30] - **Defense and Homeland Security**: Notable growth in the detection business for radiological and chemical threats, with potential revenue increases of $20 million next year [38][39] Emerging Markets and Opportunities - **Semiconductor and AI**: Strong demand in metrology for high-performance computing and AI applications, expected to grow from 8% to potentially 12% of total revenue [45][46] - **China Market**: Potential for stimulus-driven growth in high-end research tools, although timing remains uncertain [51][52] Strategic Developments - **Cell Analysis and Diagnostics**: Launch of a new benchtop product aimed at broadening market access for antibody discovery and cell line selection [54][55] - **Spatial Biology**: Continued investment in spatial biology technologies, enhancing capabilities in multi-omics and improving throughput and detection efficiency [61][62] Conclusion - Bruker is positioned for growth through innovative product offerings in mass spectrometry and proteomics, despite facing challenges in academic funding and market uncertainties. The company is strategically focusing on high-growth areas such as biopharma, diagnostics, and advanced manufacturing technologies.

Core Viewpoint - The article highlights the significant innovations introduced by Bruker at the ASMS 2025 conference, particularly the launch of the timsOmni™, timsMetabo™, and proteoElute™ systems, which are expected to advance research in proteomics and metabolomics significantly [1][2][3]. Group A: timsOmni™ Mass Spectrometry System - The timsOmni™ system is a revolutionary mass spectrometry platform designed for in-depth analysis of biomolecular structures, particularly in the fields of scientific research, drug development, clinical studies, and biopharmaceutical quality control [3]. - It features a multi-modal eXd capture technology that allows precise electronic energy control, ion accumulation, and adjustable reaction times, supporting various fragmentation methods for comprehensive structural information [3][5]. - The system is particularly adept at identifying low-abundance protein variants associated with diseases such as cancer and neurodegenerative disorders, enhancing the understanding of protein function and pathology [5][7]. Group B: OmniScape™ Software - OmniScape™ is a new generation protein sequencing analysis software that supports data analysis from the timsOmni™ system, offering advanced algorithms for complex spectrum deconvolution and protein identification [5][9]. - It transforms complex eXd fragmentation spectra into biologically relevant information, facilitating the study of functional proteomics [5][9]. Group C: timsMetabo™ Mass Spectrometry System - The timsMetabo™ system is a high-performance 4D mass spectrometry instrument that enhances small molecule analysis and integrates seamlessly with high-sensitivity proteomics [10][12]. - It introduces the "MoRE" scanning mode, which significantly improves sensitivity, separation capability, and annotation reliability for metabolomics studies [12][14]. - The system generates unique digital metabolomic profiles for each sample, enhancing the reliability of analysis results and supporting AI applications in metabolomics [14]. Group D: proteoElute™ Nanoflow Liquid Chromatography System - The proteoElute™ system is designed to provide sensitive and robust solutions for proteomics, particularly in analyzing protein variants and complex biological samples [15][16]. - It features the TwinScape™ technology for real-time system monitoring and proactive maintenance, ensuring reliable performance even with low sample volumes [16]. - The new PepSep® Advanced chromatography column enhances peak shape and resolution, improving peptide and protein identification rates by approximately 20% and 10%, respectively [17].

Financial Data and Key Metrics Changes - The meeting confirmed that a quorum was present with over 95% of shares entitled to vote represented [3][4] - The compensation of $20.24 paid to named executive officers was approved by a non-binding advisory vote [10] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed in the meeting Market Data and Key Metrics Changes - No specific market data or key metrics were discussed in the meeting Company Strategy and Development Direction and Industry Competition - The company proposed the adoption of the 2026 Incentive Compensation Plan, indicating a focus on aligning executive compensation with long-term performance [7][10] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting Other Important Information - The appointment of PricewaterhouseCoopers as the independent registered public accounting firm for fiscal year 2025 was ratified [10] - Four Class I directors were elected to hold office until the 2028 Annual Meeting of Stockholders [10] Q&A Session All Questions and Answers - No questions were raised during the meeting, and the formal business concluded without further discussion [11][12]

Core Viewpoint - Bruker Corporation reported a strong Q1 2025 performance with an 11.0% revenue growth, but maintains a cautious outlook for the full year due to anticipated impacts from reduced U.S. research funding, estimating a revenue hit of $100 million [1][11]. Revenue Performance - Q1 2025 revenue reached $801.4 million, up from $721.7 million in Q1 2024, reflecting an 11.0% increase. Organic growth for the quarter was 2.9%, while revenue growth at constant exchange rates (CER) was 12.5% [3][6]. - The core business segment, Bruker BioSpin (BSI), generated $744.5 million in revenue, a 14.3% year-over-year increase, with organic growth of 5.1% [3][6]. - The BioSpin segment's revenue included $208 million from the BioSpin division, $280.1 million from the CALID division, and $256.6 million from the Nano division [6]. Segment Analysis - The CALID segment achieved $280.1 million in revenue, driven by significant growth in microbiology and molecular diagnostics, including contributions from the newly acquired LETEC [4][6]. - The Nano segment reported $256.6 million in revenue, with high single-digit growth attributed to non-organic growth from NanoString, despite weak performance in Europe and China [4][6]. - The BEST segment saw a revenue decline to $59.3 million, down 18.9% year-over-year, with organic revenue dropping 17.7% when excluding intercompany transactions [5][6]. Strategic Developments - Bruker launched several high-performance innovative products at key conferences in Q1, including NMR systems and platforms for microbiology and molecular diagnostics, enhancing its competitive position in multi-omics and spatial biology markets [6]. - The company completed a significant acquisition of Recipharm, entering the non-infectious disease diagnostics market, which aligns with its strategy in differentiated triple quadrupole mass spectrometry [9]. Full Year Outlook - For the full year 2025, Bruker expects revenue between $3.48 billion and $3.55 billion, representing a year-over-year growth of 3.5% to 5.5% [11][13]. - The company anticipates organic revenue growth of 0% to 2%, with acquisitions contributing approximately 2.5% to revenue growth and foreign exchange effects adding about 1% [13]. - Non-GAAP earnings per share are projected to be between $2.40 and $2.48, reflecting a slight increase compared to the previous year [13].

Project Overview - The procurement project is for the purchase of field emission scanning electron microscopes and other scientific equipment for Zhengzhou University, with a total bid amount of 29.28 million [2][3]. - The project includes multiple packages, such as field emission scanning electron microscopes, mass spectrometers, and liquid chromatography mass spectrometry systems [3]. Procurement Details - The procurement method used was open bidding, with the announcement published on April 14, 2025, and the evaluation date set for May 7, 2025 [3]. - The delivery period is 180 calendar days from the effective date of the contract, and the delivery location is designated by the purchaser [3]. Bidder Information - The winning bids include: - HITACHI for a field emission scanning electron microscope at a price of 6,695,000 CNY [4]. - Bruker for a mass spectrometer at a price of 6,480,000 CNY [4]. - SCIEX for a liquid chromatography mass spectrometry system at a price of 4,990,000 CNY [5]. - Thermo Fisher Scientific for another liquid chromatography mass spectrometry system at a price of 8,220,000 CNY [5]. Quality Assurance - The quality assurance periods vary by package, with the field emission scanning electron microscope having a 5-year warranty and the mass spectrometers and liquid chromatography systems having a 3-year warranty [3].